Quarterly report · Q1
3341.TEDINET S100RN0R
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥81.8bn | 2023-04-01 → 2023-06-30 | Cons. | Net sales |
| Revenue | ¥313.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥74.7bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Operating income | ¥1.6bn | 2023-04-01 → 2023-06-30 | Cons. | Operating income |
| Operating income | ¥892m | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Ordinary income | ¥1.6bn | 2023-04-01 → 2023-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥7.7bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥913m | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥1.6bn | 2023-04-01 → 2023-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥925m | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥659m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.5bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥391m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥659m | 2023-04-01 → 2023-06-30 | Cons. | Profit loss |
| Net income | ¥391m | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Total assets | ¥199.2bn | at 2023-06-30 | Cons. | Assets |
| Total assets | ¥185.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥195.3bn | at 2022-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥142.4bn | at 2023-06-30 | Cons. | Liabilities |
| Total liabilities | ¥128.8bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥56.8bn | at 2023-06-30 | Cons. | Net assets |
| Net assets / equity | ¥56.5bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥52.9bn | at 2022-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥31.2bn | at 2023-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥23.8bn | at 2023-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥22.06 | 2023-04-01 → 2023-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥148.92 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥13.05 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 28.5% | at 2023-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.5% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.1% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-06-30 | −¥3.6bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-06-30 | −¥3.6bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-06-30 | −¥1.9bn |
| jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥72.3bn |
| jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥72.3bn |
| jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥2.9bn |
| jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥2.6bn |
| jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥2.6bn |
| jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥5m |
| jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥484m |
| jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2023-04-01 → 2023-06-30 | ¥10.5bn |
| jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2023-04-01 → 2023-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥3.6bn |
| jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2023-04-01 → 2023-06-30 | ¥126m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-06-30 | ¥85.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-06-30 | ¥81.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-06-30 | ¥3.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-06-30 | ¥3.5bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥3.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥3.8bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | −¥1.8bn |
| jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥66.4bn |
| jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥66.4bn |
| jpcrp040300-q1r_E05422-000Dispensing Pharmacy Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥2.1bn |
| jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3m |
| jpcrp040300-q1r_E05422-000Medical Professional Staffing And Placement Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥355m |
| jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥10.0bn |
| jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥6.3bn |
| jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.8bn |
| jpcrp040300-q1r_E05422-000Pharmaceutical Manufacturing And Sales Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥270m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥78.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥74.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥3.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥2.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 351
| Item | Context | Value | Unit |
|---|---|---|---|
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |